RSS Alerts

Events & Training for June 2016

Infectious Diseases World Summit

01 June 2016 - 03 June 2016

We are pleased to invite you to attend GTCbio's Infectious Diseases World Summit, which will take place June 1-3, 2016 in San Diego, CA. This event seeks to provide a forum for leaders to get the most comprehensive and wide-reaching perspective on issues, challenges, and advances in the field. The Summit is comprised of the following four conferences happening over the course of three days: 5th Antiviral Research & Development Top researchers will share their experiences with new inhibitory mechanisms, longer acting drugs, and strategies en route for cures. Delegates have the unique opportunity to network with colleagues from different sectors and gain fresh perspective on the research in antiviral drugs. 2nd Bugs & Drugs: Antibacterial Drug Discovery The increase and spread of antibiotic-resistance and the reduced investment by the pharmaceutical industry have given us an unsettling glimpse of a post-antibiotic era. Ultimately, it is the goal of the scientific community, and certainly that of the attendees, to forestall that event and to prevent the serious consequences that would come inevitably from it. 14th Vaccines Research & Development Newly emerging infections have opened up dialogue about the need for novel treatments and government response to such infections. As we continue to search for solutions, we must review the lessons learned from research and industry response in order to overcome the current challenges. 13th Anti-Infectives Partnering & Deal-Making Over the years, the anti-Infectives field has faced the same challenges in areas such as pricing and reimbursement and overcoming resistance in diseases. However, drug approvals over the past year and President Obama's recent proposal to spend $1.2 billion to address antimicrobial resistance are indications that the field is still changing and evolving.

Catamaran Resort, San Diego, CA, USA

Pre-Filled Syringes West Coast

06 June 2016 - 07 June 2016

Join us today and be part of the discussion with elite PFS industry experts. This must-attend meeting will provide a unique and intimate networking platform for you to meet decision makers in the PFS market in the West Coast. Building on SMi’s PFS community, this West Coast event is tailored for the regional market needs, delving into the core of R&D and technology advancements of combination products within PFS. We are delighted to give you our best to date speaker panel featuring key PFS leaders from Xeris Pharmaceuticals, Teva Pharmaceticals, Pfizer, Alkermes, Biogen, Genentech, Shire, MedImmune, Merck, Sharp & Dohme Corp and many more. Through practical case studies from pharma and interactive discussions, you will: • Learn about the A-Z of extractables and leachables to ensure a holistic PFS safety assessment • Keep your patients at heart: embedding human factors into device design • Update on new PFS material selection and innovation in device design for combination products • Understand regulators’ expectations and adhere to strict visual and PFS manufacturing inspection standards • Discuss, debate and benchmark against peers’ best practice to stay ahead of the competition

Hyatt Regency Mission Bay, San Diego, CA, USA

Alzheimer's Disease Therapeutics - are we making progress towards a disease modifying treatment for patients?

10 June 2016

Alzheimer’s disease is arguably the largest healthcare issue of our time, with over 45 million people currently diagnosed with dementia worldwide. With the single biggest risk factor being age, this number is only going to increase as our populations’ age. The human impact of this is huge for patients and their families, but the financial impact to our health care systems is also going to be enormous. In the US alone, Alzheimer’s disease is the 6th leading cause of death, with over 5.4 million people affected and health care costs in excess of $400 billion and expected to rise to over $1 trillion by 2050. Alzheimer’s disease pathology is highly complex, but is believed to be principally the result of an inter-play between the toxic proteins beta-amyloid and tau and driven by several genetic and environmental risk factors. Current treatments focus on treating cognitive and behavioural symptoms but have only modest effects and duration of efficacy. Alzheimer’s disease has no cure or even therapeutics which slows the progression of this disease, although a number are currently in clinical development. So it is clear that there is a huge need to find treatment options for patients and their families. While considerable resources have been directed towards finding “disease modifying” drugs by multiple pharmaceutical and biotechnology companies, the results from several large clinical trials have been mixed. This symposium will look at the progress that the field has made over recent years in attempting to target different aspects and stages of Alzheimer’s disease pathology and what lessons have been learned. It will also look at the current biological mechanisms under clinical and pre-clinical evaluation, together with exploring how new and developing genetic insights into the disease are directing us to novel mechanisms for potential new treatment options. Leading experts from industry and academia have been brought together for an exciting symposium to review, challenge and debate this complex disease biology and to address the critical question - “Are we making progress towards a disease modifying treatment for patients?”

'Living Tomorrow' Conference Centre Indringingsweg 1, 1800 Vilvoorde, Brussels, Belgium

Immunogenicity

13 June 2016 - 14 June 2016

Immunogenicity of an antigen is frequently encountered in the context of vaccine development, an area of intense interest currently due to the emergence or re-emergence of infectious pathogens with the potential for worldwide spread. With the global vaccine market expected to reach $84.44 billion by 2022, now is the time engage with industry experts to addresses the real challenges with immunogenicity including assay assessment, the role of aggregation, the introduction of nanobodies and many more! This year’s conference will allow you to: gain insight into how to tackle the challenges involved with the assessment of early risks in immunogenicity; hear key feedback from regulatory authorities on how to increase your speed to market as well as participate in insightful discussions on; nanobodies, ADCs, biosimilars and much more!

Holiday Inn Kensington Forum, London, UK

11th Annual ADMET conference and exhibition

13 June 2016 - 14 June 2016

ADMET 2016 will provide a series of practical case studies, interactive roundtables and panel discussions facilitated by leading industry experts that will provide executives with useful tools and best practices to: • Discover application of PBPK to drug development in rare diseases • Review the role of drug transporters in drug delivery to CNS diseases • Learn about better models for understanding, predicting and avoiding drug induced liver injury • Discuss in silico approaches to evidence-based mechanistic modelling • Analyse early dose predictions – a valuable tool in risk assessment and optimisation of small molecules

Holiday Inn Kensington Forum, London, UK

6th BioBanking Event

20 June 2016 - 21 June 2016

SMi presents the 6th annual Biobanking Conference which takes place on 20 – 21 June 2016 in London. The upcoming proposed Data Protection Regulation in the EU is the culmination of biobanking operations and will constitute a new legal framework if and once passed but the European Commission. As such, this year’s Biobanking Conference will focus on the potential changes and impacts of maintaining a sustainable biobanking infrastructure, harmonisation and interaction between biobanks across UK, Europe and the world. Expert speaker panel line-up includes the European Commission, MHRA, UK Biobank, Roslin Cell Sciences, European Culture Collection ECACC, and other leading European Biobanks. Key benefits: Spotlight session - Creating a biobank for drug discovery • Hear the latest updates on Data Protection Act from European Commission and UK Biobank • Learn about the integration of biobanking in drug development • Obtain an overview of how to build a model of next generation biobank • Discover the latest updates on biobanking in the 21st Century You can download the conference brochure on http://www.bio-banking-event.com/ddt.Register online by 31 March 2016 and save £400.

Holiday Inn Kensington Forum, London, UK

Copyright © 2025
Elsevier Ltd. All rights reserved.
Sitemap | Terms & Conditions | Privacy | | Website Design Working with water